Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
(Reuters) - Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.